Search Results
Active Filters
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
Feb 11, 2026, 17:31 ET EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
1093), AbbVie (NYSE: ABBV), Teligene, Bristol–Myers Squibb (NYSE: BMY), SystImmune, Black Diamond Therapeutics (NASDAQ: BDTX), Lantern Pharma (NASDAQ: LTRN), and others, are developing new EGFR-NSCLC treatment drugs that can be available in the EGFR-NSCLC market in the coming years. The promising
More news about: DelveInsight Business Research, LLP